Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Oligonucleotide Therapy CRO Services
From in vitro knockdown screening to in vivo survival outcomes—Cyagen delivers end-to-end CRO services tailored for ASO, siRNA, and precision gene modulation therapies.
Your End-to-End Path to Oligo Therapeutics
Cyagen’s platform is purpose-built for the unique demands of oligonucleotide therapeutics—ensuring precise evaluation of ASO and siRNA drugs across molecular, cellular, and organismal levels. Our full-cycle services span from early screening to in vivo validation, all within a unified system that delivers consistency, reproducibility, and translational value.
{{ item.title }}
{{static_tabs[0].title}}
Silence. Confirm. De-risk.
Validate target modulation through molecular and functional assays.
Establish the efficacy of oligonucleotide drugs at the molecular level by confirming their ability to reduce gene expression in vitro. Cyagen provides a full suite of assays—including mRNA quantification and protein-level confirmation—to ensure your ASO, siRNA, or gene-targeting construct hits the intended target with high specificity.
Cyagen’s in vitro knockdown validation services include:
  • qPCR & RT-qPCR: Quantitative analysis of mRNA knockdown levels
  • Western Blot / ELISA / IF: Confirm reduced protein expression
  • Dual-dosing Validation: Compare knockdown performance across delivery routes (e.g., ICV vs. SC)
These assays offer the first checkpoint in confirming oligo activity before in vivo studies begin.
{{static_tabs[1].title}}
Replicate. Predict. Translate.
Use clinically relevant HUGO-GT™ models for oligo drug development.
Cyagen’s HUGO-GT™ humanized mouse models enable accurate evaluation of oligonucleotide therapies in vivo. These models feature full human sequence replacement of key gene loci—ensuring compatibility with ASO, siRNA, and CRISPR-based drugs. With validated models for SMA, ALS, Alzheimer’s disease, RP, and more, we support precise pharmacodynamic assessments tailored to your therapy’s genetic target.
Base Strain
Search for Models
Search
Catalog Number Name Base Strain Research Application Action
{{ value.product_num || "--" }} {{ value.product_name || "--" }} {{ value.product_strain || "--" }}
{{v2}};
Inquire
Previous Page
Next Page
Can't Find Your Model?
If your desired model isn't listed, our experts are here to help! Request a Custom Animal Model →
{{static_tabs[2].title}}
Deliver. Track. Optimize.
Evaluate compound uptake and tissue targeting across ICV, IV, and SC routes.
We provide tailored delivery strategies and quantitative analyses to evaluate ASO, siRNA, or other oligonucleotide biodistribution in vivo.
  • Supported delivery routes: Intracerebroventricular (ICV), intravenous (IV), and subcutaneous (SC) injection
  • Quantitative assessment: Fluorescence imaging, RT-qPCR, and histological analysis
These tools ensure accurate evaluation of compound exposure and tissue localization—critical for therapeutic optimization.
{{static_tabs[3].title}}
Evaluate. Quantify. Validate.
Multilevel pharmacodynamic readouts—molecular, cellular, histological, and functional—ensure robust efficacy assessment.
Cyagen’s PD platform offers a full range of validated assays to evaluate oligonucleotide drug performance in vivo and in vitro. Whether quantifying SMN expression in SMA models or assessing visual and motor function recovery, our customizable evaluation pipeline delivers reliable, publication-ready data.
Evaluation Type Description
Molecular Assays qPCR, Western blot, ELISA for gene and protein expression profiling.
Cellular Assays Viability, apoptosis, and proliferation assays for assessing cellular response.
Histological Readouts H&E, IHC, and immunofluorescence to evaluate tissue structure and target markers.
Functional Readouts ERG and behavior tests (e.g., motor and cognitive assessments) for efficacy validation.
Need Evaluation Support? Tell us about your study goals!
Our team will help design a tailored PD and safety evaluation plan. Return to Workflow Navigation >>
Case Highlight - ASO Efficacy in SMA Humanized Mouse Model
Restored SMN Expression & Improved Motor Neuron Survival
Treatment with ASO-10-27 significantly increased SMN protein levels and motor neuron counts in B6-hSMN2 mice, as demonstrated by western blot and ChAT immunostaining.
Figure 1. ASO treatment increased SMN expression and motor neuron count in B6-hSMN2 mice, confirmed by western blot and ChAT immunostaining after ICV and SC injection.
Extended Survival and Delayed Disease Onset
B6-hSMN2 mice receiving ASO-10-27 via ICV injection exhibited markedly improved survival and delayed disease symptoms compared to untreated controls.
Figure 2. ASO-10-27 treatment improved survival and delayed disease symptoms in B6-hSMN2 mice, with reduced toe necrosis and preserved tail integrity at 78 days post-injection.
Our Unique Advantages
Humanized Models Optimized for ASO/siRNA
Access our exclusive HUGO-GT™ mouse models with full-length human gene replacement—ideal for evaluating ASO, siRNA, and gene modulation therapies targeting human-specific sequences.
Proven Preclinical Study Experience
Work with a team backed by successful case studies in oligonucleotide drug development across CNS, neuromuscular, and ophthalmic diseases.
Integrated CRO Platform from In Vitro to In Vivo
Seamlessly transition from in vitro knockdown assays to in vivo pharmacology and biodistribution—ensuring consistency and scientific rigor at every step.
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Inquiry Details
Main Area of Research
Service(s) of Interest
Project Details
Contact Information
Full Name
Email
Phone Number
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest